Aqualung Takes Genomic Approach to COVID-19’s Killer Lung Inflammation
Targets Protein Linked To Acute Respiratory Distress Syndrome
Executive Summary
Acute respiratory distress syndrome is one of the prime causes behind the mounting global death toll of COVID-19, but there are currently no FDA-approved treatments. Armed with biomarker and genotyping assays, Aqualung hopes to speed its antibody candidate into development by next year.
You may also be interested in...
Investor Faith In David Hung’s Nuvation Renewed By Anheart Buyout
The acquisition brings two potential best-in-class cancer therapies, which could make Nuvation a commercial company as soon as 2025.
Vertex Joins Regulus In Kidney Disease Therapy Hunt
The Boston, MA biotech is about to enter the clinic with its autosomal dominant polycystic kidney disease candidate but microRNA therapy pioneer Regulus is already setting the pace.
Stoke’s Persistence Pays Off With Dravet Syndrome Therapy
Results showing a 74% reduction in seizures set up Stoke for a pivotal study and could make STK-001 the first disease-modifying agent for the condition.